NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 10 12:49PM ET
0.3508
Dollar change
-0.0152
Percentage change
-4.15
%
Index- P/E- EPS (ttm)-0.09 Insider Own31.76% Shs Outstand80.88M Perf Week14.27%
Market Cap29.43M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float57.25M Perf Month11.72%
Enterprise Value29.26M PEG- EPS next Q- Inst Own3.41% Short Float0.92% Perf Quarter29.97%
Income-7.12M P/S23.17 EPS this Y- Inst Trans0.09% Short Ratio0.62 Perf Half Y2.39%
Sales1.27M P/B4.48 EPS next Y- ROA-76.37% Short Interest0.53M Perf YTD4.40%
Book/sh0.08 P/C71.77 EPS next 5Y- ROE-104.33% 52W High0.50 -29.56% Perf Year-14.94%
Cash/sh0.00 P/FCF- EPS past 3/5Y32.33% 12.85% ROIC-109.99% 52W Low0.25 38.93% Perf 3Y-31.63%
Dividend Est.- EV/EBITDA- Sales past 3/5Y47.38% -20.77% Gross Margin4.33% Volatility6.93% 4.51% Perf 5Y-37.50%
Dividend TTM- EV/Sales23.04 EPS Y/Y TTM56.57% Oper. Margin-585.84% ATR (14)0.02 Perf 10Y-12.30%
Dividend Ex-Date- Quick Ratio0.68 Sales Y/Y TTM-5.50% Profit Margin-560.27% RSI (14)66.97 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.28 EPS Q/Q66.06% SMA2012.61% Beta1.47 Target Price3.88
Payout- Debt/Eq0.04 Sales Q/Q11.86% SMA5013.31% Rel Volume145.29 Prev Close0.37
Employees70 LT Debt/Eq0.02 EarningsJun 30 BMO SMA2005.84% Avg Volume850.16K Price0.35
IPOApr 13, 2006 Option/ShortYes / Yes EPS/Sales Surpr.0.00% -14.75% Trades Volume66,051,921 Change-4.15%
Jun-30-25 09:00AM
Jun-27-25 05:45PM
Jun-23-25 08:30AM
May-30-25 05:25PM
May-22-25 09:30AM
09:30AM Loading…
May-12-25 09:30AM
Apr-24-25 09:30AM
Apr-09-25 09:35AM
Mar-17-25 09:00AM
Mar-12-25 09:00AM
Mar-10-25 09:00AM
Mar-04-25 09:00AM
Feb-21-25 09:25AM
Feb-20-25 09:00AM
Feb-18-25 08:30AM
08:30AM Loading…
Feb-11-25 08:30AM
Jan-28-25 08:30AM
Jan-21-25 08:30AM
Jan-13-25 08:30AM
Jan-08-25 08:30AM
Dec-19-24 07:00PM
Dec-02-24 08:30AM
Nov-25-24 08:30AM
Nov-14-24 08:30AM
Nov-06-24 08:30AM
Oct-17-24 08:30AM
Oct-03-24 09:00AM
Sep-18-24 08:00AM
Sep-04-24 08:00AM
Aug-26-24 07:00PM
09:00AM Loading…
Aug-22-24 09:00AM
Aug-20-24 08:00AM
Aug-08-24 09:30PM
Jul-18-24 09:00AM
Jul-09-24 09:10AM
Jun-25-24 09:00AM
Jun-24-24 07:30PM
Jun-18-24 09:00AM
Jun-10-24 09:00AM
May-28-24 09:00AM
May-21-24 02:00PM
May-09-24 08:45AM
Apr-16-24 07:00AM
Apr-09-24 09:00AM
Apr-03-24 09:00AM
Mar-26-24 03:00PM
Mar-20-24 11:00AM
07:00AM
Mar-19-24 04:00PM
Mar-12-24 03:00PM
Feb-28-24 01:00PM
Feb-23-24 12:01PM
Feb-16-24 07:05PM
Feb-01-24 09:20AM
Jan-23-24 09:20AM
Jan-17-24 09:20AM
Dec-19-23 09:20AM
Dec-13-23 09:30AM
Dec-06-23 08:30AM
Nov-21-23 08:30AM
Nov-13-23 08:00AM
Oct-19-23 03:30PM
Aug-21-23 02:30PM
Aug-14-23 08:30AM
Aug-02-23 08:30AM
Jul-18-23 05:22AM
Jul-12-23 08:44AM
Jul-07-23 09:15AM
Jul-06-23 07:46AM
Jun-06-23 09:20AM
Jun-05-23 08:30AM
May-18-23 08:30AM
Apr-24-23 09:00AM
Apr-18-23 08:30AM
Mar-22-23 08:30AM
Mar-20-23 08:45AM
Feb-14-23 07:41PM
Feb-08-23 08:30AM
Jan-04-23 08:00AM
Dec-20-22 08:30AM
Dec-07-22 08:30AM
Dec-01-22 08:30AM
Nov-30-22 11:19AM
Nov-01-22 04:30PM
Sep-21-22 06:00AM
Sep-12-22 07:00AM
Aug-08-22 06:00AM
Jun-22-22 11:26PM
Jun-21-22 12:15AM
Jun-08-22 09:03PM
Apr-18-22 05:28PM
Mar-23-22 04:55PM
Feb-10-22 04:30PM
Jan-19-22 09:29AM
Dec-14-21 09:25AM
Dec-08-21 05:43PM
Dec-02-21 09:32AM
Oct-29-21 10:09PM
Oct-15-21 04:00PM
Sep-07-21 07:30PM
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran James PDirectorSep 25 '24Buy0.34588,235200,000942,402Sep 27 04:05 PM
PRINS RICHARD KDirectorAug 12 '24Proposed Sale0.39200,00078,200Aug 09 06:03 PM